Stocktoria
NOVAVAX INC NVAX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1973-05-16
NOVAVAX INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 40.3% | -36.5% | -57.6% | -32.5% | -147.1% |
| Net margin | 39.2% | -27.5% | -55.4% | -33.2% | -152.1% |
| Return on assets | 37.4% | -12.0% | -30.3% | -29.1% | -67.7% |
| Return on equity | -344.7% | 30.1% | 76.0% | 103.8% | 495.8% |
| Debt / equity | -1.91× | — | — | — | — |
| Current ratio | 2.13 | 0.98 | 0.70 | 0.69 | 0.90 |
| Revenue growth | 64.7% | -30.7% | -50.4% | 72.9% | 141.0% |
Source: SEC EDGAR filings · CIK 0001000694 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.